Buy Zyban (Bupropion 150mg SR) Online - Sun Pharma Generic NDRI Smoking Cessation Antidepressant Therapy
Zyban (Bupropion 150mg SR) represents the foundational non-nicotine antidepressant smoking cessation medication and the only NDRI (norepinephrine-dopamine reuptake inhibitor) approved for smoking cessation. Originally developed by GlaxoSmithKline and FDA-approved as Zyban in 1997, bupropion established itself as the first non-nicotine pharmacological therapy for smoking cessation and remains widely used first-line therapy alongside varenicline (Chantix) and nicotine replacement therapy. The distinctive feature of Zyban is its dual pharmacological identity — the same bupropion active ingredient is marketed as Wellbutrin for depression treatment providing potential dual benefit for smokers with concurrent depression or mood disturbances during cessation attempts. Manufactured by Sun Pharmaceutical Industries Ltd. India — one of the world's top-5 generic pharmaceutical manufacturers — Zyban provides bioequivalent generic bupropion at accessible cost. Available as sibling smoking cessation product to Chantix (varenicline — Pfizer + Healing Pharma) offering patients pharmacological choice based on individual patient characteristics, comorbidities, and prior treatment history.
Bupropion works through norepinephrine-dopamine reuptake inhibition (NDRI) — a unique pharmacological class among antidepressants — combined with weak nicotinic acetylcholine receptor antagonism. First, bupropion inhibits norepinephrine reuptake increasing synaptic norepinephrine improving mood and reducing withdrawal symptoms. Second, it inhibits dopamine reuptake increasing synaptic dopamine providing partial reward pathway support during nicotine withdrawal. Third, bupropion weakly blocks nicotinic acetylcholine receptors reducing nicotine reinforcement effects. Fourth, this multi-mechanism approach reduces cravings and withdrawal symptoms while addressing potential mood disturbances during quit attempts. Clinical trials demonstrate 30-35 percent end-of-treatment abstinence versus 15 percent placebo — approximately doubling quit rates.
Zyban serves smoking cessation as its primary FDA-approved indication. Particularly beneficial for smokers with concurrent depression or mood disturbances due to dual antidepressant benefit. Standard treatment: 7-12 week course with optional maintenance extension. Best outcomes when combined with behavioral counseling.
Zyban dosed 150 mg once daily for 3 days then 150 mg BID. Set quit date week 2. Take morning and midday (not evening) to avoid insomnia. BLACK BOX WARNING for suicidality. Seizure risk — contraindicated with seizure disorders and eating disorders.
Free prescription
Discrete packaging
Have questions?
Quality Assurance
- Nicotine Dependence Treatment: Multi-mechanism therapy addressing both cravings and mood component of nicotine addiction cessation;
- Depression Prone Smoker Cessation: Ideal for smokers with history of depression or mood disturbances given dual antidepressant benefit;
- Post Quit Depression Prevention: Antidepressant properties may reduce risk of post-cessation depression common in vulnerable individuals;
- Long Time Smoker Cessation: Effective for chronic smokers who have failed nicotine replacement therapy alone in previous attempts;
- NDRI Cessation Therapy: Only norepinephrine-dopamine reuptake inhibitor approved for smoking cessation offering unique pharmacological approach;
- Non Nicotine Cessation Therapy: Nicotine-free medication for patients preferring completely non-nicotine cessation approach without patches or gum;
- Failed NRT Cessation Attempts: Alternative for patients who have failed nicotine patches gum or lozenges alone in previous quit attempts;
- Combined Cessation Therapy: Can be combined with nicotine patch for superior efficacy compared to either monotherapy alone;
- Cardiovascular Patient Cessation: Effective smoking cessation for cardiovascular disease patients requiring risk reduction;
- COPD Patient Smoking Cessation: Essential cessation therapy for COPD patients where continued smoking accelerates disease progression;
- Cancer Patient Cessation: Smoking cessation before during and after cancer treatment improves outcomes and reduces recurrence;
- Combined with Behavioral Counseling: Optimal outcomes when combined with counseling doubling cessation success rates;
- Depression Comorbidity Management: Concurrent management of smoking and mood disturbances common in patients with mental health history;
- Weight Concerned Smokers: Less post-cessation weight gain compared to other cessation approaches - important motivational factor;
- Non Addictive Cessation Medication: Non-controlled non-addictive medication without dependence risks common with nicotine replacement;
- Once or Twice Daily Dosing: Simple dosing regimen improves treatment adherence during vulnerable early quit period;
- Long Term Abstinence Support: 7-12 week standard course with optional extended maintenance for high-relapse-risk patients;
- Adjunct Bupropion Cessation Therapy: Same molecule as Wellbutrin used for depression providing therapeutic overlap for combined conditions;
- Generic Zyban Cessation Therapy: Bioequivalent Sun Pharma generic alternative providing accessible cost first-line smoking cessation therapy.
- Dual Antidepressant Purpose: Same molecule as Wellbutrin - particularly beneficial for smokers experiencing mood disturbances or depression during quit attempts;
- Non Nicotine Medication: Nicotine-free approach for patients preferring completely nicotine-free cessation therapy without NRT patches or gum;
- Better Convenient Oral Dosing: Simple oral tablet dosing starting two weeks before quit date providing convenient treatment approach;
- Better Improved Quit Rates: Clinical trials show approximately doubles quit rates compared to placebo through pharmacological support;
- Better Long Term Abstinence Support: Extended treatment courses possible for maintenance during vulnerable relapse period after initial cessation;
- Non Addictive Support: Bupropion itself non-addictive and non-controlled unlike nicotine replacement products maintaining nicotine dependence;
- Better Once or Twice Daily Dosing: Simple dosing schedule (150 mg BID after initial titration) improves adherence during treatment;
- Better Psychological Benefits: Addresses neurological aspects of nicotine addiction managing psychological cravings and behavioral habits associated with smoking;
- Helps Quit Smoking Reduces Withdrawal Syndrome: Comprehensive nicotine dependence treatment providing multi-mechanism support during cessation period;
- Better Mood Support During Quit: Antidepressant activity provides mood support during cessation reducing risk of post-cessation depression;
- Less Post Cessation Weight Gain: Less post-quit weight gain compared to other cessation approaches - important motivational factor for weight-concerned smokers;
- Better Depression Comorbidity Management: Concurrent treatment of both smoking and depression provides efficient management of common comorbid conditions;
- Better Sun Pharma Manufacturing Quality: Sun Pharmaceutical Industries WHO-GMP certified manufacturing - top-5 global generic pharma quality standards;
- Better Failed NRT Alternative: Effective option for patients who have failed nicotine replacement therapy alone in previous quit attempts;
- Better Combined with NRT Option: Can be combined with nicotine patch for superior efficacy providing multi-modal cessation approach;
- Better Combined with Counseling: Combining Zyban with behavioral counseling significantly increases chances of long-term smoking cessation success;
- Better Cardiovascular Risk Reduction: Successful smoking cessation dramatically reduces cardiovascular disease morbidity and mortality risks over subsequent years;
- Better Cancer Risk Reduction: Smoking cessation substantially reduces risk of lung head neck bladder and other tobacco-related cancers;
- Better Quality of Life: Successful smoking cessation dramatically improves quality of life energy taste sense of smell and overall wellbeing.
Generic Zyban (Bupropion 150 mg) Medication guide:
BLACK BOX WARNING - SUICIDALITY: Zyban (bupropion) is an antidepressant medication carrying an FDA Black Box Warning for increased risk of suicidal thoughts and behaviors particularly in children, adolescents, and young adults (up to age 24). Monitor for worsening depression, unusual behavior changes, or emergence of suicidal thoughts particularly during initial weeks of therapy and dose changes. This warning applies to all antidepressants and remains active for bupropion. Patients should be monitored closely and family/friends should be alert to warning signs.
Zyban (Bupropion 150mg SR) represents the foundational non-nicotine antidepressant smoking cessation medication and the only NDRI (norepinephrine-dopamine reuptake inhibitor) approved for smoking cessation. Originally developed by GlaxoSmithKline and FDA-approved as Zyban in 1997, bupropion established itself as the first non-nicotine pharmacological therapy for smoking cessation and remains widely used first-line therapy alongside varenicline (Chantix) and nicotine replacement therapy. The distinctive feature of Zyban is its dual pharmacological identity — the same bupropion active ingredient is marketed as Wellbutrin for depression treatment providing potential dual benefit for smokers with concurrent depression or mood disturbances during cessation attempts. Manufactured by Sun Pharmaceutical Industries Ltd. India — one of the world's top-5 generic pharmaceutical manufacturers — Zyban provides bioequivalent generic bupropion at accessible cost. This comprehensive medication guide covers every aspect of Zyban therapy from bupropion pharmacology through NDRI mechanism, dual pharmacological identity with Wellbutrin, titration protocol, timing strategies for avoiding insomnia, combination with behavioral counseling and NRT, comparison with Chantix (varenicline), and critical safety considerations including seizure risk and Black Box Warning monitoring.
💊 Introduction to Zyban
Zyban is a prescription oral medication containing bupropion hydrochloride as its active ingredient in 150 mg sustained-release (SR) tablet form manufactured by Sun Pharmaceutical Industries Ltd. India. Bupropion was developed by GlaxoSmithKline (GSK) — originally as antidepressant Wellbutrin (FDA-approved 1985) — and subsequently received FDA approval as Zyban in 1997 for smoking cessation. This dual approval established a unique clinical situation where the same active ingredient (bupropion) exists as two distinct branded products for two different indications — a rare pharmaceutical circumstance reflecting bupropion multi-mechanism action.
Zyban established itself as the first non-nicotine pharmacological therapy approved for smoking cessation, providing an important alternative to nicotine replacement therapy (NRT). This first-in-class status opened the therapeutic category to non-nicotine approaches that eventually led to development of varenicline (Chantix — approved 2006) and demonstrated that mood/reward pathway modulation could support smoking cessation independent of nicotine substitution.
The Zyban brand on rxshop.md is manufactured by Sun Pharmaceutical Industries Ltd. — one of the world top-5 generic pharmaceutical manufacturers with headquarters in Mumbai India. Sun Pharma maintains WHO-GMP certification, US FDA-inspected facilities, and EU-GMP certification providing quality manufacturing across multiple therapeutic categories. Sun Pharma is the same manufacturer producing multiple other products available on rxshop.md including Naprosyn (pain medicine), Theo-24 (respiratory), Absorica (isotretinoin globally), and Motrin (pain medicine). Sun Pharma manufactures bupropion generic bioequivalent to brand-name GSK Zyban providing accessible cost alternative while maintaining therapeutic equivalence.
🧬 Understanding Bupropion as Wellbutrin/Zyban Dual Identity
Understanding the dual pharmaceutical identity of bupropion is essential for appreciating this medication clinical positioning and potential therapeutic overlap benefits.
Same Molecule, Two Brand Names, Two Indications
Bupropion pharmaceutical dual identity:
- Wellbutrin (SR/XL): FDA-approved 1985 for depression - GSK antidepressant brand
- Zyban: FDA-approved 1997 for smoking cessation - GSK smoking cessation brand
- Same active ingredient: Bupropion hydrochloride in both products
- Same manufacturer: GlaxoSmithKline originally for both indications
- Different marketing: Distinct branding to prevent confusion for different clinical uses
- Same pharmacology: Identical mechanism, pharmacokinetics, side effects
- Overlapping benefits: Depression treatment may benefit smoking cessation and vice versa
- Cannot use both simultaneously: Same drug - dose would double
Zyban vs Chantix Sibling Comparison
| Property | Zyban (Bupropion) | Chantix (Varenicline) |
|---|---|---|
| Manufacturer on rxshop | Sun Pharmaceutical | Pfizer + Healing Pharma |
| Drug class | NDRI antidepressant | α4β2 nicotinic partial agonist |
| Mechanism | Norepinephrine + dopamine reuptake inhibition | Direct nicotinic receptor action |
| Strength | 150 mg SR | 1 mg |
| FDA approval year | 1997 | 2006 |
| 1-year quit rate | ~18-20 percent | ~26 percent |
| Antidepressant benefit | Yes (dual purpose) | No |
| Combined with NRT | Yes - superior to either alone | Generally not combined |
| Black Box Warning | Suicidality (active) | Removed 2016 |
| Seizure risk | Significant - dose-related | Rare |
| Weight gain post-quit | Less weight gain | Similar to NRT |
| Best for depression comorbidity | Yes - ideal choice | Alternative |
Sun Pharmaceutical Industries Manufacturing
Sun Pharmaceutical Industries credentials:
- One of world top-5 generic pharmaceutical manufacturers globally
- Founded 1983 - over 40 years pharmaceutical experience
- Headquarters: Mumbai India with global operations
- WHO-GMP certification - highest quality standards
- US FDA-inspected facilities serving American market
- EU-GMP certification serving European market
- Serves 150+ countries globally
- Multiple rxshop.md products including Naprosyn Theo-24 Absorica Motrin
- Extensive generic portfolio across all major therapeutic categories
🧪 Chemistry and NDRI Mechanism
Bupropion has the chemical formula C13H18ClNO with molecular weight approximately 239.7 g/mol. Chemically, bupropion is a monocyclic aminoketone antidepressant — structurally distinct from tricyclic antidepressants, SSRIs, and other antidepressant classes. This unique chemical structure explains bupropion's distinctive pharmacological profile and lack of pharmacological overlap with other antidepressants.
NDRI Mechanism of Action
Bupropion multi-mechanism action:
- Norepinephrine reuptake inhibition: Blocks norepinephrine transporter (NET) increasing synaptic norepinephrine
- Dopamine reuptake inhibition: Blocks dopamine transporter (DAT) increasing synaptic dopamine particularly in reward pathways
- Weak nicotinic acetylcholine receptor antagonism: Blocks α3β4 and other nicotinic receptor subtypes reducing nicotine reinforcement
- Antidepressant effect: NDRI action produces mood elevation similar to SSRIs but different mechanism
- Reward pathway modulation: Dopamine increase in nucleus accumbens partially substitutes for nicotine reward
- Withdrawal symptom reduction: Norepinephrine increase reduces anxiety and irritability of nicotine withdrawal
- Craving reduction: Combined mechanism reduces subjective nicotine cravings
- No serotonin effects: Unlike SSRIs bupropion does not affect serotonin - explains different side effect profile
How Bupropion Differs from Chantix
Understanding how bupropion mechanism differs from varenicline explains why these two medications have different efficacy, side effect, and safety profiles despite both being non-nicotine smoking cessation approaches:
- Bupropion: Increases neurotransmitters upstream of nicotine receptors - indirect mechanism
- Varenicline: Directly binds nicotine receptors - direct mechanism
- Bupropion advantage: Antidepressant benefit for mood-disturbed smokers
- Varenicline advantage: More effective for smoking cessation efficacy
- Bupropion side effects: Insomnia, dry mouth - typical antidepressant profile
- Varenicline side effects: Nausea, vivid dreams - typical nicotinic profile
- Bupropion safety concerns: Seizure risk, Black Box Warning suicidality
- Varenicline safety concerns: Nausea, previously psychiatric (warning removed)
Pharmacokinetic Profile
| Parameter | Value | Clinical Significance |
|---|---|---|
| Oral bioavailability | Approximately 87 percent | Good absorption |
| Time to peak (SR formulation) | 3 hours | Steady-release peaks |
| Half-life (parent) | 21 hours | Once/twice daily dosing |
| Half-life (metabolites) | 21-37 hours | Active metabolites contribute |
| Protein binding | Approximately 84 percent | Substantial protein binding |
| Metabolism | Hepatic - CYP2B6 primarily | Drug interactions with CYP2B6 modifiers |
| Active metabolites | Hydroxybupropion (major) | Contributes to activity |
| Elimination | Renal (as metabolites) | Renal function affects clearance |
| Steady state | Approximately 5 days | Delay in full effect |
| Onset of cessation effect | 2 weeks after starting | Why quit date 2 weeks after start |
🎯 Approved Indications
Primary FDA Approved Indication
- Smoking cessation aid in adults with tobacco dependence
Same Molecule Also Approved For (Wellbutrin brand)
- Major depressive disorder (Wellbutrin brand)
- Seasonal affective disorder (Wellbutrin XL brand)
Broader Clinical Uses
- Long-term smokers who have failed previous cessation attempts
- Depression-prone smokers particularly beneficial dual purpose
- Post-quit depression prevention in vulnerable individuals
- Weight-concerned smokers - less post-cessation weight gain
- Combined with NRT for superior efficacy
- Cardiovascular patients requiring smoking cessation
- COPD patients where continued smoking accelerates disease
- Cancer patients requiring cessation
- Extended maintenance for high-risk relapse patients
Off-Label Uses
- ADHD adjunctive therapy: Off-label but some evidence
- Sexual dysfunction from SSRIs: Reversal of SSRI-induced sexual side effects
- Weight management: As component of naltrexone-bupropion combination (Contrave)
- Bipolar depression: Sometimes used carefully with mood stabilizer
Ideal Patient Selection
Zyban particularly appropriate for:
- Smokers with concurrent depression or history of depression
- Smokers concerned about post-cessation weight gain
- Patients preferring non-nicotine cessation approach
- Patients who failed NRT alone in previous quit attempts
- Patients wanting combined NRT + medication approach
- Motivated smokers ready to quit and comply with treatment protocol
- Patients without seizure disorders or eating disorders
- Patients not on MAOIs or other contraindicated medications
- Patients able to attend follow-up for monitoring
🚫 Contraindications
Absolute Contraindications
- Seizure disorder history - bupropion lowers seizure threshold
- Current or prior diagnosis of bulimia or anorexia nervosa - higher seizure risk
- Concurrent MAOI use - hypertensive crisis risk (14-day washout required)
- Concurrent other bupropion products (Wellbutrin) - double dose seizure risk
- Abrupt discontinuation of alcohol or benzodiazepines - seizure risk elevated
- Hypersensitivity to bupropion or any excipient
- Severe allergic reactions to prior bupropion exposure
Precautions
Use with caution in:
- History of head trauma: Increased seizure risk
- Brain tumors or CNS lesions: Increased seizure risk
- Severe hepatic impairment: Reduced dose - 150 mg every other day maximum
- Renal impairment: Dose reduction may be needed
- Pregnancy: Category C - avoid unless clearly indicated
- Breastfeeding: Excreted in breast milk - avoid
- Bipolar disorder: Risk of mania - use with mood stabilizer
- History of psychosis: May worsen psychotic symptoms
- Diabetes mellitus: May affect glucose control
- Concurrent alcohol use: Increased seizure risk
- Elderly: More sensitive to side effects
- Children under 18: Not established for cessation use
Black Box Warning - Suicidality Monitoring
CRITICAL FDA Black Box Warning:
All antidepressants including bupropion carry FDA Black Box Warning for increased risk of suicidal thoughts and behaviors particularly in children, adolescents, and young adults up to age 24 during initial treatment period and dose changes.
Monitoring requirements:
- Baseline screening: Depression, suicidal ideation, anxiety history
- Weekly monitoring: First 4 weeks of treatment
- Every 2 weeks: Weeks 4-8 of treatment
- At each visit: Assess for worsening mood, behavior changes, suicidal thoughts
- Warning signs: Agitation, restlessness, hostility, unusual behavior changes
- Family/friend awareness: Educate about warning signs to watch for
- Access to psychiatric support: Ensure available if needed
- Discontinue if concerning: Low threshold for discontinuation
💉 Dosage and Titration Protocol
Standard Zyban Dosing Protocol
Standard Zyban titration:
- Days 1-3: 150 mg once daily (morning)
- Day 4 through week 12: 150 mg twice daily (morning and midday)
- Doses spaced at least 8 hours apart: Reduces seizure risk
- Do NOT take within 4-6 hours of bedtime: Prevents insomnia
- Set quit date week 2: Days 8-14 after starting
- Continue for 7-12 weeks: Complete recommended course
- Extended maintenance: Additional courses possible for high-relapse-risk patients
Timing to Avoid Insomnia
Optimal timing strategy:
- Morning dose: With or shortly after breakfast (7-8 AM typical)
- Midday dose: With or after lunch (12-2 PM typical)
- Minimum 8 hours between doses: Prevents seizure risk from concentration spikes
- Avoid evening doses: Insomnia common if taken within 4-6 hours of bedtime
- Take with food: May reduce nausea
- Consistent timing: Same times daily improves compliance
- Do not double doses: If missed, skip to next scheduled dose
Quit Date Strategy
- Set quit date within week 2 of starting Zyban (days 8-14)
- Continue smoking during week 1: Allows steady-state achievement
- Full therapeutic effect requires 2 weeks: Peak steady-state ~5 days
- Commit to quit date: Do not delay indefinitely
- Continue Zyban after quit date: Full 7-12 week course
- Consider extended maintenance: For high-risk relapse patients
Combined with Behavioral Counseling
Optimal combined approach:
- Behavioral counseling: Individual or group cognitive-behavioral therapy
- Motivational interviewing: Enhance commitment to quit
- Quitline support: Phone-based counseling programs
- Text message support: Digital cessation support programs
- Trigger identification: Recognize and manage smoking cues
- Coping skills training: Alternative responses to cravings
- Social support: Family, friends, cessation groups
- Regular follow-up: Especially during vulnerable early quit period
- Doubles cessation rates: Vs medication alone
Combination with NRT (Nicotine Replacement Therapy)
Zyban can be combined with NRT for enhanced efficacy:
- Zyban + nicotine patch: Superior to either alone in clinical trials
- Approximate quit rates: 30-35% combination vs 20% Zyban alone vs 17% patch alone
- Mechanisms complementary: NDRI + nicotine substitution address different aspects
- Different from Chantix approach: Generally not combined with NRT
- Monitor for interactions: Increased blood pressure possible
- Discuss combination with prescriber for individualized approach
📊 Clinical Effectiveness Data
| Metric | Response Data |
|---|---|
| End-of-treatment abstinence (12 weeks) | 30-35 percent vs 15 percent placebo |
| 6-month continuous abstinence | Approximately 22 percent vs 10 percent placebo |
| 12-month continuous abstinence | Approximately 18-20 percent vs 10 percent placebo |
| Comparison to Chantix | Chantix approximately 50% more effective |
| Comparison to placebo | Approximately doubles quit rates |
| Comparison to nicotine patch | Similar to slightly superior |
| Combined with NRT patch | Superior to either alone |
| Combined with counseling | Approximately doubles cessation rates |
| Weight gain post-cessation | Less than NRT or Chantix |
⚠️ Side Effects
Very Common Side Effects
- Insomnia: Very common (30-40 percent) - manage with timing strategy
- Dry mouth: Very common
- Headache: Common
- Constipation: Common
- Nausea: Common
- Anxiety or nervousness: Common
- Tremor: Occasional
- Blurred vision: Occasional
Managing Insomnia
Insomnia management strategies:
- Timing critical: Take morning and midday, avoid evening dose
- Last dose 6+ hours before bed: Minimum required
- Sleep hygiene: Consistent bedtime, cool dark room
- Avoid caffeine afternoon: Amplifies insomnia
- Regular exercise: Not immediately before bed
- Consider dose reduction: If severe - discuss with prescriber
- Typically improves: Insomnia often subsides after first weeks
Serious Adverse Events
Seek immediate medical attention for:
- Seizures: Any seizure activity - discontinue immediately
- Severe allergic reactions: Angioedema, difficulty breathing
- Suicidal thoughts or severe depression
- Manic or hypomanic episodes: Elevated mood, decreased need for sleep
- Psychotic symptoms: Hallucinations, delusions
- Severe skin reactions: Stevens-Johnson syndrome
- Elevated blood pressure: Severe hypertension
- Confusion or altered mental status
- Aggressive or hostile behavior
🔄 Drug Interactions
| Drug/Substance | Interaction |
|---|---|
| MAOIs (phenelzine, tranylcypromine) | CONTRAINDICATED - hypertensive crisis risk (14-day washout required) |
| Other bupropion products (Wellbutrin) | CONTRAINDICATED - dose doubling, seizure risk |
| Alcohol | Increased seizure risk - avoid or minimize |
| Other seizure-lowering drugs | Additive seizure risk - avoid combinations |
| SSRIs and SNRIs | May increase bupropion effects - monitor |
| Warfarin | Smoking cessation affects warfarin - monitor INR |
| Theophylline | Smoking cessation increases levels + bupropion effects |
| CYP2B6 inhibitors (clopidogrel) | May increase bupropion levels |
| Tamoxifen | Bupropion inhibits CYP2D6 - reduces tamoxifen efficacy |
| Nicotine replacement therapy | Can be combined for enhanced efficacy - monitor BP |
| Digoxin | May decrease digoxin exposure |
🛡️ Special Populations
- Depression-Prone Smokers
- Ideal candidates for Zyban. Dual antidepressant benefit addresses both smoking and mood. May reduce post-cessation depression risk. First-line choice when both indications present.
- Elderly Patients
- Standard dosing typically appropriate. Consider renal and hepatic function. More sensitive to side effects. Monitor blood pressure. Cardiovascular benefits of cessation particularly important in elderly.
- Pregnancy
- Category C - avoid unless clearly indicated. Behavioral interventions preferred first-line during pregnancy. If pharmacological therapy needed, discuss risk-benefit with obstetrician.
- Lactation
- Bupropion excreted in breast milk - avoid during breastfeeding. Alternative cessation approaches preferred while nursing.
- Children/Adolescents Under 18
- Not FDA-approved for smoking cessation. Increased suicidality risk per Black Box Warning. Behavioral interventions preferred.
- Seizure Disorder History
- CONTRAINDICATED. Bupropion lowers seizure threshold. Use Chantix or NRT instead.
- Eating Disorder History
- CONTRAINDICATED. Bulimia and anorexia associated with higher seizure risk on bupropion. Use alternative therapy.
- Bipolar Disorder
- Risk of switching to mania - use only with concurrent mood stabilizer under psychiatric supervision. Consider alternative cessation therapy.
- Alcohol Use Disorder
- Increased seizure risk with alcohol - especially concerning during withdrawal. Careful consideration of alternatives needed.
- Renal Impairment
- May require dose reduction. Monitor for accumulation. Consider 150 mg daily maximum for moderate impairment.
- Hepatic Impairment
- Severe hepatic impairment requires dose reduction to 150 mg every other day maximum. Mild-moderate impairment may need adjustment.
- Cardiovascular Disease
- Monitor blood pressure and cardiovascular symptoms. Smoking cessation benefits substantial in CV disease. Beneficial with careful monitoring.
📆 Long-Term Follow-Up
Post-treatment considerations:
- Relapse risk highest first 3 months: Continue vigilance
- Continue behavioral support: Cessation is chronic process
- Weight monitoring: Less weight gain than NRT but still monitor
- Trigger management: Identify and manage relapse triggers
- Depression screening: Monitor for post-cessation depression
- Long-term follow-up: Physician periodic check-in
- Repeat course option: Available for relapse patients
- Health benefits progressive: Continue improving for years after cessation
📦 Storage and Handling
- Store at room temperature between 15°C and 30°C (59°F and 86°F)
- Protect from moisture and light
- Keep tablets in original packaging
- Keep out of reach of children and pets
- Do not use past expiration date
- Do not share medication with others
- Do NOT crush or chew SR tablets - alters release profile
- Return unused medication to pharmacy for proper disposal
👨⚕️ When to Contact Your Doctor
- Any seizure activity - immediate emergency evaluation
- Suicidal thoughts or severe depression
- Severe mood changes: agitation, aggression, hostility, mania
- Signs of allergic reaction: angioedema, difficulty breathing
- Serious skin reactions: rash, blistering, fever
- Severe insomnia not managed by timing changes
- Elevated blood pressure or cardiovascular symptoms
- New psychotic symptoms: hallucinations, delusions
- Concurrent alcohol or benzodiazepine withdrawal
- Suspected pregnancy - discontinue immediately
- Concurrent MAOI use required (must washout Zyban first)
- Persistent smoking despite full treatment course
- Signs of relapse after quit date
- Questions about combining with NRT
- Kidney or liver function changes
- Development of new medical conditions
- Considering extended maintenance therapy
🌟 Key Takeaways
Essential points about Zyban (bupropion) therapy:
- Zyban is Sun Pharmaceutical Industries generic bupropion 150 mg SR tablets
- First non-nicotine smoking cessation medication FDA-approved 1997
- Only NDRI (norepinephrine-dopamine reuptake inhibitor) approved for smoking cessation
- Same molecule as Wellbutrin (antidepressant) - dual pharmaceutical identity
- Sibling to Chantix (varenicline) on rxshop but different mechanism
- Chantix approximately 50% more effective, Zyban better for depression comorbidity
- 30-35% end-of-treatment abstinence vs 15% placebo
- ~18-20% one-year abstinence vs 10% placebo (approximately doubles quit rate)
- Standard dosing: 150 mg daily days 1-3, then 150 mg BID days 4+
- Take morning and midday to avoid insomnia - not evening
- Set quit date week 2 (days 8-14) after starting
- Complete 7-12 week treatment course
- BLACK BOX WARNING for suicidality (antidepressant class effect)
- Seizure risk - dose-related
- CONTRAINDICATED: Seizure disorders, eating disorders, MAOIs
- Common insomnia manageable with proper timing
- Can be combined with NRT for superior efficacy
- Less post-cessation weight gain than other cessation approaches
- Best combined with behavioral counseling - doubles cessation rates
- Do NOT combine with Wellbutrin (same drug - double dose seizure risk)
- Sun Pharmaceutical Industries top-5 global generic pharma quality
CRITICAL Medical Disclaimer: This medication guide provides general information about Zyban (bupropion 150 mg SR tablets Sun Pharmaceutical Industries) and does not constitute individualized medical advice. Every patient situation is unique and requires evaluation by a qualified healthcare provider. Zyban carries an FDA BLACK BOX WARNING for increased risk of suicidal thoughts and behaviors particularly in children adolescents and young adults up to age 24 - close monitoring required particularly during initial weeks of therapy and dose changes. Bupropion CONTRAINDICATED in patients with seizure disorders, eating disorders (bulimia/anorexia), concurrent MAOI use (14-day washout required), abrupt alcohol or benzodiazepine discontinuation, or other bupropion products (Wellbutrin) as double dosing dramatically increases seizure risk. Never take other bupropion products (Wellbutrin/Wellbutrin SR/Wellbutrin XL) simultaneously with Zyban. Standard dosing 150 mg once daily days 1-3 then 150 mg BID days 4+ - do not exceed. Take morning and midday, avoid evening doses to prevent insomnia. Doses must be spaced at least 8 hours apart. Set quit date week 2 after starting. Complete 7-12 week treatment course. Report seizures immediately (emergency evaluation). Report suicidal thoughts, severe mood changes, allergic reactions, or serious skin reactions promptly. Can be combined with nicotine patch for superior efficacy but discuss with prescriber first. Best outcomes when combined with behavioral counseling. Do not use during pregnancy or breastfeeding unless clearly indicated. Renal or hepatic impairment may require dose reduction. If you experience concerning symptoms contact your healthcare provider promptly. The information provided here should complement but never replace direct professional medical guidance.
Zyban — Frequently Asked Questions
-
What is Zyban used for?
Zyban is used to help people stop smoking by reducing cravings and withdrawal effects. -
How does Zyban work to help quit smoking?
Zyban works by affecting neurotransmitters in the brain, which helps to reduce cravings and withdrawal symptoms associated with quitting smoking. -
When should I start taking Zyban?
It's recommended to start taking Zyban one to two weeks before your quit date to allow it to build up in your body. -
How long do I need to take Zyban?
The typical course for Zyban is about 7 to 12 weeks, but your healthcare provider will determine the length of treatment based on your individual needs. -
Can Zyban be used alongside nicotine replacement therapy (NRT)?
Yes, Zyban can be used in combination with NRTs for improved effectiveness, but always consult with a healthcare provider before combining treatments. -
What are the common side effects of Zyban?
Common side effects include dry mouth, insomnia, and headaches. Most side effects are mild and temporary. -
Is Zyban addictive?
No, Zyban is not considered addictive and is a non-nicotine aid to help quit smoking.
More Smoking Cessation Medications
